Abarelix
Abarelix was the first GnRH antagonist for prostate cancer, approved in the United States in 2003 for men who could not take agonists, but allergic reactions restricted it and it was withdrawn from the US market in 2005; it remained available in Germany.
Overview
Abarelix lowers testosterone to castrate levels within about a week without the flare seen with leuprolide or goserelin, which made it useful for men with impending spinal cord compression or severe bone pain. The FDA approved it in 2003 under a restricted programme because of immediate-onset systemic allergic reactions, and the manufacturer withdrew it from the US market in 2005. It was later approved in Germany. Degarelix, approved in 2008, took over the GnRH antagonist role in most countries.
Blocks the pituitary GnRH receptor directly, so luteinising hormone and testosterone fall within days without the initial testosterone surge that GnRH agonists cause. Connects to GnRH receptor (GNRHR).
1.Abarelix binds GnRH receptor (GNRHR).
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2003 | Advanced symptomatic prostate cancer in men who cannot take GnRH agonists (restricted programme) · Withdrawn from the US market in 2005 |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Abarelix" OR ABSTRACT:"Abarelix" OR TITLE:"Plenaxis" OR ABSTRACT:"Plenaxis") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Abarelix, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentHistrelin
Shares GnRH receptor (GNRHR), Leuprolide (leuprorelin) and GnRH agonists, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer and the tag chembl-universe.
- TreatmentBuserelin
Shares GnRH receptor (GNRHR), Leuprolide (leuprorelin) and GnRH agonists, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer and the tag chembl-universe.
- TreatmentDiethylstilbestrol
Shares Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer and the tag chembl-universe.
- TreatmentAminoglutethimide
Shares Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer and the tag chembl-universe.
- TreatmentFluoxymesterone
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentFormestane
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag chembl-universe.
- TreatmentCholine C-11
Shares Prostate cancer and the tag chembl-universe.
- CompanyTolmar
Shares GnRH receptor (GNRHR), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer.